Navigating Horizon BCBS Omnia Skyrizi Prior Authorization
Successfully managing Horizon BCBS Omnia Skyrizi prior authorization is critical for patient access and revenue cycle efficiency. Klivira automates the complex ePA process for this specific payer plan and specialty medication.
For revenue cycle directors and prior authorization coordinators, the specific requirements for high-cost specialty drugs like Skyrizi (risankizumab) under distinct plans such as Horizon BCBS Omnia present unique challenges. Efficiently navigating these payer-specific workflows is essential to minimize delays, reduce administrative burden, and ensure timely patient care for conditions like plaque psoriasis, psoriatic arthritis, and Crohn's disease.
Understanding Horizon BCBS Omnia's Formulary for Skyrizi
Skyrizi, an IL-23 inhibitor, is typically classified as a specialty medication across most formularies, including Horizon BCBS Omnia. This often places it on a higher formulary tier, necessitating a comprehensive prior authorization (PA) process. Horizon BCBS commonly partners with Prime Therapeutics as its pharmacy benefit manager (PBM), which dictates the specific formulary and PA criteria for specialty drugs like risankizumab.
Key Prior Authorization Criteria for Skyrizi (risankizumab)
Prior authorization for Skyrizi under Horizon BCBS Omnia typically involves stringent medical necessity reviews. Common hurdles include step-therapy protocols requiring documented failure or contraindication to less costly alternatives, such as conventional systemic therapies or other biologics. Quantity limits are also standard, often aligning with FDA-approved dosing regimens for indications like plaque psoriasis, psoriatic arthritis, and Crohn's disease.
Common Documentation Requirements for Skyrizi PA
- Patient's diagnosis (ICD-10 codes) and relevant clinical history.
- Documentation of previous treatment failures or contraindications to alternative therapies (e.g., TNF-alpha inhibitors).
- Physician's notes detailing disease severity and rationale for Skyrizi.
- Laboratory results supporting diagnosis or ruling out other conditions.
- Medication history, including start/stop dates and reasons for discontinuation of prior treatments.
Streamlining Horizon BCBS Omnia Skyrizi Prior Authorization Submissions
Klivira integrates directly with EMR systems to automate the submission of Horizon BCBS Omnia Skyrizi prior authorization requests. By leveraging SMART on FHIR and supporting X12 278 transactions, our platform ensures that all required clinical data is accurately compiled and transmitted. This approach minimizes manual data entry, reduces the likelihood of incomplete submissions, and accelerates the entire ePA process for risankizumab.
Enhancing Efficiency and Compliance for IL-23 Inhibitor PAs
Automating prior authorizations for specialty drugs like Skyrizi not only improves turnaround times but also enhances compliance with payer-specific guidelines. Klivira's system is designed to adapt to the evolving criteria from PBMs like Prime Therapeutics, ensuring that submissions meet the latest requirements for Horizon BCBS Omnia members. This proactive approach helps reduce denials and improves the overall financial health of your practice.
Frequently asked questions
What is the typical formulary tier for Skyrizi with Horizon BCBS Omnia?
Skyrizi (risankizumab) is generally placed on a specialty tier within Horizon BCBS Omnia formularies, consistent with most high-cost biologic medications. This classification necessitates a comprehensive prior authorization process before coverage can be approved.
What are common step-therapy requirements for Skyrizi under Horizon BCBS Omnia?
Horizon BCBS Omnia typically requires documented failure or contraindication to conventional systemic therapies or other biologics before approving Skyrizi. This step-therapy protocol is common for IL-23 inhibitors used in conditions like psoriasis, psoriatic arthritis, and Crohn's disease.
Does Horizon BCBS Omnia accept electronic prior authorization (ePA) for Skyrizi?
Yes, Horizon BCBS Omnia, often through its PBM Prime Therapeutics, generally accepts electronic prior authorization (ePA) submissions. Utilizing ePA platforms like Klivira can significantly expedite the Horizon BCBS Omnia Skyrizi prior authorization process and improve efficiency.
Which PBM manages Skyrizi benefits for Horizon BCBS Omnia members?
For many Horizon BCBS plans, including Omnia, Prime Therapeutics serves as the pharmacy benefit manager (PBM). Prime Therapeutics is responsible for managing the formulary, negotiating drug prices, and establishing prior authorization criteria for specialty medications like Skyrizi.
How can Klivira improve Skyrizi prior authorization workflows for Horizon BCBS Omnia?
Klivira automates the data extraction and submission process for Horizon BCBS Omnia Skyrizi prior authorizations, integrating directly with EMRs. This reduces manual effort, ensures accurate data submission, and proactively addresses payer-specific requirements, leading to faster approvals and fewer denials.
Related coverage
Ready to automate prior auth for this plan?
See how Klivira automates prior authorizations for your team.
Request a demo